Kyverna Therapeutics Secures $147.5M, Extends Runway into 2028, Advances Lead CAR T Programs

summarizeSummary

Kyverna Therapeutics reported strong Q4/FY2025 results, secured $147.5 million in financing to extend its cash runway into 2028, and announced significant clinical progress for its miv-cel CAR T programs, including anticipated BLA submission for stiff person syndrome in 1H 2026.

check_boxKey Events

• Extended Cash Runway

  Kyverna reported $279.3 million in cash, cash equivalents, and marketable securities as of December 31, 2025, providing an expected cash runway into 2028. This funding supports the SPS BLA filing, commercial launch, and Phase 3 gMG trial.

• Successful Capital Raise

  The company strengthened its balance sheet by raising a total of $147.5 million, including $122.5 million in gross proceeds from follow-on financing and ATM program sales, and an initial $25 million from a $150 million milestone-based loan facility.

• SPS Program Advancement

  Kyverna anticipates submitting its Biologics License Application (BLA) for miv-cel in stiff person syndrome (SPS) in the first half of 2026, following landmark positive Phase 2 data, and expects to be launch-ready by year-end 2026.

• gMG Phase 3 Progress

  The company is progressing its FDA-aligned Phase 3 clinical trial for generalized myasthenia gravis (gMG), building on positive interim Phase 2 data.

auto_awesomeAnalysis

This 8-K, furnishing the company's latest press release, provides a comprehensive update on Kyverna Therapeutics' strong financial position and significant clinical advancements. The company successfully raised $122.5 million through equity sales and secured an initial $25 million from a new loan facility, extending its cash runway into 2028. This funding is critical for advancing its lead miv-cel CAR T programs, including the anticipated Biologics License Application (BLA) submission for stiff person syndrome (SPS) in the first half of 2026 and progression of its Phase 3 trial for generalized myasthenia gravis (gMG). While the equity raise was substantially dilutive, the successful securing of capital and the positive clinical milestones significantly de-risk the company's operational future and path to commercialization for its first-in-class therapies. Investors should monitor the upcoming BLA submission and clinical data presentations.